Pharmacodynamics of recombinant IFN-β during long-term treatment of malignant melanoma

Journal of Interferon and Cytokine Research

Volumn 16, Issue 10, 1996, Pages 777-781

  Fierlbeck, G ^a   Ulmer, A ^a   Schreiner, T ^a   Stroebel, W ^a   Schiebel, U ^a   Brzoska, J ^b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b Rentschler Biotechnology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2',5' OLIGOADENYLATE SYNTHETASE; BETA 2 MICROGLOBULIN; INTERFERON ANTIBODY; NEOPTERIN; NEUTRALIZING ANTIBODY; RECOMBINANT BETA INTERFERON;

ADULT; ARTICLE; CELL STRAIN K 562; CHO CELL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; FEMALE; HUMAN; HUMAN CELL; IMMUNOMODULATION; MALE; MELANOMA; NATURAL KILLER CELL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

CRICETINAE; CRICETULUS GRISEUS;

EID: 0029860644     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.1996.16.777     Document Type: Article

References (37)

1. HAWKINS, M., HORNING, S., KONRAD, M., ANDERSON, S., SIELAFF, K., ROSNO, S., SCHIESEL, J., DAVIS, T., DEMETS, D., MERIGAN, T., and BORDEN, E. (1985). Phase I evaluation of a synthetic mutant of β-interferon. Cancer Res. 45, 5914-5920.
2. MICHALEVICZ, R., ADERKA, D., FRISCH, B., and REVEL, M. (1988). Interferon-beta induced remission in a hairy cell leukemia patient resistant to interferon-alpha. Leukemia Res. 12, 845-851.
3. GOODKIN, D.E. (1994). Interferon-beta-1b. Lancet 344, 1057-1060.
4. BARON, S., and DIANZANI, F. (1994). The interferons: a biological system with therapeutic potential in viral infections. Antiviral Res. 24, 97-110.
5. LANDOLFO, S., GRIBAUDO, G., ANGERETTI, A., and GARIGLIO, M. (1995). Mechanisms of viral inhibition by interferons. Pharm. Ther. 65, 415-442.
6. BARON, S., TYRING, S.K., FLEISCHMANN, W.R., COPPENHAVER, D.H., NIESEL, D.W., KLIMPEL, G.R., STANTON, G.J., and HUGHES, T.K. (1991). The interferons: mechanisms of action and clinical applications. JAMA 266, 1375-1383.
7. BORDEN, E.C. (1992). Interferons: pleiotropic cellular modulators. Clin. Immunol. Immunopathol. 62, S18-S24.
8. HERTZOG, P.J., HWANG, S.Y., and KOLA, I. (1994). Role of interferons in the regulation of cell proliferation, differentiation, and development. Mol. Reprod. Dev. 39, 226-232.
9. BRZOSKA, J., and OBERT, H.-J. (1990). Immunomodulating effects of interferons: conclusions for therapy. In: Genital Papillomavirus Infections. G. Gross, S. Jablonska, H. Pfister, and H.E. Stegner (eds.) Berlin, Heidelberg, New York: Springer-Verlag, pp. 379-391.
10. KROWN, S.E. (1988). Interferons in malignancy: biological products or biological response modifiers? J. Natl. Cancer Inst. 80, 306-309.
11. GOLDSTEIN, D., SIELAFF, K.M., STORER, B.E., BROWN, R.R., DATTA, S.P., WITT, P.L., TEITELBAUM, A.P., SMALLEY, R.V., and BORDEN, E.C. (1989). Human biologic response modification by interferon in the absence of measurable serum concentrations: a comparative trial of subcutaneous and intravenous interferon-β serine. J. Natl. Cancer Inst. 81, 1061-1068.
12. FIERLBECK, G., SCHIEBEL, U., BRUCHELT, G., HANDGRETINGER, R., and BRZOSKA, J. (1990). Pharmacokinetic and immunological investigations in patients treated with recombinant interferon beta. J. Interferon Res. 10, S126.
13. SCHILLER, J.H., STORER, B., PAULNOCK, D.M., BROWN, R.R., DATTA, S.P., WITT, P.L., and BORDEN, E.C. (1990). A direct comparison of biological response modulation and clinical side effects by interferon-betaser, interferon-gamma, or the combination of interferons betaser and gamma in humans. J. Clin. Invest. 86, 1211-1221.
14. ALAM, J., GORMAN, B., STANNARD, M., DAWSON, A., LYONDS, P., MANT, T., and FOX, I. (1991). Clinical pharmacology of recombinant beta interferon in humans. J. Interferon Res. 11, S246.
15. BRUCHELT, G., FIERLBECK, G., SCHIEBEL, U., BOGENSCHÜTZ, O., RASSNER, G., and NIETHAMMER, D. (1992). Determination of 2′-5′-oligoadenylate synthetase in serum and peripheral blood mononuclear cells before and after subcutaneous application of recombinant interferon beta and gamma. Eur. J. Clin. Chem. Clin. Biochem. 30, 521-528.
16. LIBERATI, A.M., HORISBERGER, M.A., PALMISANO, L., ASTOLFI, S., NASTARI, A., MECHATI, S., VILLA, A., MANCINI, S., ARZANO, S., and GRIGNANI, F. (1992). Double-blind randomized phase I study on the clinical tolerance and biological effects of natural and recombinant interferon-β. Interferon Res. 12, 329-336.
17. LIBERATI, A.M., GAROFANI, P., DE ANGELIS, V., DI CLEMENTE, F., HORISBERGER, M., CECCHINI, M., BETTI, A.R., PALMISANO, L., ASTOLFI, S., NASTARI, A., VILLA, A., and ARZANO, S. (1994). Double-blind randomized phase I study on the clinical tolerance and pharmacodynamics of natural and recombinant interferon-β given intravenously. J. Interferon Res. 14, 61-69.
18. WITT, P.L., SPEAR, G.T., HELGESON, D.O., LINDSTROM, M.J., SMALLEY, R.V., and BORDEN, E.C. (1990). Basal and interferon-induced 2′-5′-oligoadenylate synthetase in human monocytes, lymphocytes, and peritoneal macrophages. J. Interferon Res. 10, 393-402.
19. WITT, P.L., STORER, B.E., BRYAN, G.T., BROWN, R.R., FLASHNER, M., LAROCCA, A.T., COLBY, C.B., and BORDEN, E.C. (1993). Pharmacodynamics of biological response in vivo after single and multiple doses of interferon-β. J. Immunother. 13, 191-200.
20. REISER, W., and HAUSER, H. (1987). Recombinant human interferon beta from mammalian cell lines. Arzneim-Forsch./Drug Res. 37, 482-485.
21. BÖYUM, A. (1968). Separation of leukocytes from blood and bone marrow. Scand. J. Clin. Lab. Invest. 21, 77-82.
22. SCHATTNER, A., MERLIN, G., WALLACH, D., ROSENBERG, H., BINO, T., HAHN, T., LEVIN, S., and REVEL, M. (1981). Monitoring of interferon therapy by assay of (2′-5′) oligoisoadenylate synthetase in human peripheral white blood cells. J. Interferon Res. 1, 587-594.
23. 51Cr-labelled allogenic target cells in vivo: inhibition by isoantibody and by drugs. Immunology 14, 181-196.
24. JONDAL, M., and PROSS, H. (1975). Surface markers on human B and T-lymphocytes. VI. Cytotoxicity against cell lines as a functional marker for lymphocyte subpopulations. Int. J. Cancer 15, 596-601.
25. 1) leukemia cell line: transplantation into athymic mice. J. Natl. Cancer Inst. 56, 627-629.
26. JACOBS, L., and JOHNSON, K.P. (1994). A brief history of the use of interferons as treatment of multiple sclerosis. Arch. Neurol. 51, 1245-1252.
27. BORDEN, E.C., HAWKINS, M.J., SIELAFF, K.M., STORER, B.M., SCHIESEL, J.D., and SMALLEY, R.V. (1988). Clinical and biological effects of recombinant interferon-β administered intravenously daily in phase I trial. J. Interferon Res. 8, 357-366.
28. SPEAR, G.T., PAULNOCK, D.M., JORDAN, R.L., MELTZER, D.M., MERRIT, J.A., and BORDEN, E.C. (1987). Enhancement of monocyte class I and II histocompatibility antigen expression in man by in vivo β-interferon. Clin. Exp. Immunol. 69, 107-115.
29. WACHTER, H.D., FUCHS, D., HAUSEN, A., REIBNEGGER, G., and WERNER, E.R. (1989). Neopterin as marker for activation of cellular immunity. Adv. Clin. Chem. 27, 81-141.
30. FUCHS, D., BAIER-BITTERLICH, G., HAUSEN, A., MURR, C., WEISS, G., WERNER, E.R., WERNER-FELMAYER, G., and REIBNEGGER, G. (1995). Neopterin als immundiagnostische Messgrösse. Deutsch. Med. Wochenschr. 120, 567-570.
31. 2. Clin. Immunol. Immunopathol. 37, 236-244.
32. BRAVO CUELLAR, A., MARTIN RUIZ, I.L., and ORBACHARBOUYS, S. (1985). Decreased natural killer cell activity after prolonged administration of interferon in cancer patients. Immunol. Lett. 10, 137-139.
33. HERSEY, P., MACDONALD, M., HALL, C.H., SPURLING, A., EDWARDS, A., COATES, A., and McCARTHY, W. (1986). Immunological effects of recombinant interferon alfa-2a in patients with disseminated melanoma. Cancer 57, 1666-1674.
34. TEICHMANN, J.V., SIEBER, G., LUDWIG, W.D., and RUEHL, H. (1989). Immunosuppressive effects of recombinant interferon-α during long-term treatment of cancer patients. Cancer 63, 1990-1993.
35. HERLBECK, G., and SCHREINER, T. (1994). Incidence and clinical significance of therapy-induced neutralizing antibodies against interferon-β. J. Interferon Res. 14, 205-206.
36. BARTSCH, H.H., PFIZENMAIER, K., HANUSCH, A., SCHEURICH, P., ÜCER, U., and NAGEL, G.A. (1989). Sequential therapy with recombinant interferons gamma and alpha in patients with unfavorable prognosis of chronic myelocytic leukemia: clinical responsiveness to recombinant IFN-α correlates with the degree of receptor down-regulation. Int. J. Cancer. 43, 235-240.
37. KLOKE, O., and NIEDERLE, N. (1990). Development and mechanism of interferon resistance. Cancer Treat. Rev. 17(Suppl. A), 81-88.